Global Miglustat API market was valued at USD 202.46 million in 2023 and is projected to reach USD 253.23 million by 2029, exhibiting a steady CAGR of 3.80% during the forecast period.  Miglustat API, a small molecule glucosylceramide synthase inhibitor, has emerged as a critical therapeutic agent primarily used for treating Gaucher disease type 1 and Niemann-Pick disease type...